ISTH 2023 Congress: Late-Breakthrough Press Conference

The ISTH 2023 Press Conference will highlight several Late-Breakthrough abstracts on a diverse and extensive range of highly anticipated topics. Members of the press will have the opportunity to interview the authors about their groundbreaking research during the onsite event. 

The press conference will be moderated by Margaret Rand, Ph.D., Hospital for Sick Children and University of Toronto and Local Organizing Committee for Congress Montréal. The agenda of the press conference is as follows: 

• 2:45-2:55 p.m. - Welcome and Overview of ISTH 2023 Scientific Program, presented by Margaret Rand
• 2:55-3:05 p.m. – Emicizumab prophylaxis instead of immunosuppressive therapy in patients with acquired hemophilia A (AHA) , Andreas Tiede, M.D., Ph.D., Hannover Medical School, Hannover, Germany
• 3:05-3:15 p.m. – Rare Germline Loss of Function Variants in SERPINH1 (HSP47) are Associated with Increased Risk of Thrombosis , Amelia Haj, M.D., Ph.D., Massachusetts General Hospital, Massachusetts, United States
• 3:15-3:35 p.m. – Distinct Antibody Groups in Patients With Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) and their Clinical Implications Ishac Nazy, Ph.D., McMaster University, Ontario, Canada
• 3:25-3:35 p.m.- Targeted thromboprophylaxis in patients with lower limb trauma requiring immobilization: stepped wedge randomized trial , Delphine Douillet, M.D., Ph.D., Emergency Department, Centre Hospitalier Universitaire d’Angres, CHU Angers, Angers, France
• 3:35-3:45 p.m. – Questions and Answers

*Please note that this press conference will not be live-streamed. If you would like to arrange one on one interviews with the authors, please contact Media Relations Manager, Melissa DiMercurio: mdimercurio@isth.org